Recent Phase 2a clinical trials demonstrate that mesenchymal stem cell therapy can slow brain atrophy by up to 62% and reduce neuroinflammation in mild Alzheimer's patients. Review of laromestrocel trial data, biomarker outcomes, and emerging treatment options.
2026 patient guide to MSC therapy for Alzheimer’s disease: how it differs from lecanemab and donanemab, who is a candidate, what outcomes to expect, the 6 active clinical trials including NCT06775964 and the first MSC + antibody drug combination trial.
Stem cell research has been a rapidly evolving field, with groundbreaking discoveries being made at an unprecedented pace. These advancements are transforming our understanding of human biology, enabling the development of innovative treatments for a wide range of diseases. We will explore some of the latest developments in stem cell...
La maladie d'Alzheimer est la principale cause de démence et les stratégies thérapeutiques actuelles ne permettent pas de prévenir, de ralentir ou de guérir la pathologie. La maladie se caractérise par une perte de mémoire, causée par la dégénérescence et la mort de cellules neuronales dans plusieurs régions du cerveau, dont l'hippocampe. Des chercheurs ont identifié un petit...
Alzheimer’s disease is the main cause of dementia and current therapeutic strategies cannot prevent, slow down or cure the pathology. The disease is characterized by memory loss, caused by the degeneration and death of neuronal cells in several regions of the brain, including the hippocampus. Researchers have identified a small...
French 
English 
Chinese 
Russian